Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group

Andrea Havasi1,2, Ashutosh Wechalekar3, Cihan Heybeli2, Nelson Leung2, Avital Angel-Korman1, Vaishali Sanchorawala2, Oliver Cohen3, Ashutosh Wechalekar4,5, Frank Bridoux6,7, Insara Jaffer7, Victoria Gutgarts7, Hani Hassoun7, Maya Levinson7, Cara Rosenbaum8, Paolo Milani5, Giovanni Palladini9, Giampaolo Merlini9, Ute Hegenbart10, Stefan Schönland10, Kaya Veelken10, Alexander Pogrebinsky1,11, Gheorghe Doros1,11 and Heather Landau7

© The Author(s) 2022

INTRODUCTION

Light chain (AL) amyloidosis is a result of extracellular deposition of pathologic, insoluble fibrils that are formed from abnormal light chains (LCs) or LC fragments. It is a systemic disease that affects various organs and is associated with an underlying clonal B-cell disorder (most commonly plasmacytic) [1, 2]. The accumulation of amyloid fibrils disrupting tissue structure and direct toxicity from circulating precursors eventually leads to organ failure and death [2–4]. Approximately 57–80% of AL amyloidosis patients have renal involvement at presentation, and up to ~40% of these patients require renal replacement therapy during the course of their disease [5–8]. A renal staging system for the prediction of ESRD using universally available measurements (i.e., proteinuria and eGFR) was validated in patients with AL amyloidosis and being used in clinical practice [7].

Until the mid-1990s, the treatment of AL amyloidosis was ineffective, resulting in a median overall survival (OS) of only 12–18 months [9, 10]. Over the last two decades, newer therapeutic regimens directed towards the toxic plasma cell clone have become available, including high dose melphalan with autologous stem cell transplantation (HDM/SCT), proteasome inhibitors (bortezomib, ixazomib), immunomodulatory drugs (pomalidomide, lenalidomide, thalidomide) and monoclonal antibodies (daratumumab) [2, 8, 11, 12]. Due to these breakthroughs in treatment, there is now a higher frequency of complete hematologic response (CR) or very good partial response (VGPR),

[1] Amyloidosis Center, Boston University School of Medicine, Boston, MA, USA. [2] Mayo Clinic, Rochester, MN, USA. [3] National Amyloidosis Centre, University College London, London, UK. [4] Department of Nephrology, CIC INSERM 1402, CHU Poitiers, Poitiers, France. [5] Centre national de référence Amylose AL & autres maladies par dépots d’immunoglobulines monoclonales, CHU Poitiers, Poitiers, France. [6] Centre National de la Recherche Scientifique UMR CNRS 7276/INSERM U1262, Université de Limoges, Limoges, France. [7] Memorial Sloan Kettering Cancer Center, New York, NY, USA. [8] Weill Cornell Medicine, New York, NY, USA. [9] Amyloidosis Research and Treatment Center, Foundation Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo and Department of Molecular Medicine, University of Pavia, Pavia, Italy. [10] Amyloidosis Center, Heidelberg University Hospital, Heidelberg, Germany. [11] Department of biostatistics, Boston University School of Public Health, Boston, MA, USA. [12] email: ahavasi@bu.edu

Received: 24 January 2022 Revised: 25 July 2022 Accepted: 28 July 2022 Published online: 18 August 2022
which has translated into improved organ response and OS [7, 8, 12–14].

Longer survival led to increased number of patients who progress to end stage renal disease (ESRD). Referral for renal transplantation in these patients has been hampered due to the initial experience of early graft loss and shorter OS from recurrence of amyloidosis in graft and/or extra-renal organs compared to patients who received renal allografts for non-amyloid indications [15, 16]. However, because of prolonged disease-free survival in the setting of effective plasma cell-directed therapies, renal transplantation has become a more realistic option.

A few amyloidosis referral centers have published their individual experience with kidney transplantation in AL amyloidosis patients, but data from larger, combined studies are lacking. A major challenge faced by transplant centers is the lack of uniform criteria to determine which patients would be suitable candidates for renal transplantation. This international collaboration set out to expand our understanding of the role of renal transplantation in AL amyloidosis and define eligibility criteria based on our findings. We analyzed the demographic, clinical, and biochemical data collected on 237 patients followed at various centers in the United States, England, France, Italy, and Germany over the past 30 years who underwent renal transplantation for AL amyloidosis.

METHODS
A total of 237 patients with ESRD from AL amyloidosis who underwent renal transplantation at various centers were included (see centers under the author’s affiliations). Patients were followed between November 1987 and September 2020. From smaller previously published series 175 patients were included [17–21]. Data were collected both prospectively and retrospectively and analyzed retrospectively. The study was approved by the Institutional Review Board in accordance with the Declaration of Helsinki and the Health Insurance Portability and Accountability Act guidelines. Only de-identified data were shared. All patients had renal involvement as evidenced by biopsy-proven amyloid deposition in their kidney, or were showing typical signs of AL amyloidosis involving the kidney (urine protein >0.5 g/day and/or renal insufficiency without other causes of proteinuria) combined with tissue diagnosis at an alternate site such as abdominal fat pad [22]. Amyloid typing was done by immunohistochemistry, immunofluorescence, immunoelectron microscopy or proteomics analysis [2]. A monoclonal light chain of the same isotype needed to be detected in the deposits and in the plasma or urine (by serum or urine immunofixation or circulating free light-chain (FLC) quantitation) [23]. Patients with multiple myeloma were excluded. After 2003 hematologic response was defined as CR, VGPR, PR, or NR as described previously [22, 24, 25]. Before 2003 a hematologic response relied on serum and urine protein electrophoresis (SPEP & UPEP) and immunofixation (IFE) as well as clonal bone marrow plasmacytosis. Serum free light chain levels were prospectively followed in all patients after 2003 and free light chain assays were also done on collected (prior to 2003) frozen sera if available. Hematologic response indicates achievement of the best hematologic response which includes at least a PR although the vast majority of patients achieved a VGPR or CR. Organ involvement by amyloidosis was determined according to the international consensus criteria [22]. Glomerular filtration rate (GFR) was estimated using the four variable Modification of Diet in Renal Disease equation for patients who were not on dialysis or CKD-EPI Creatinine Equation for patients older than 70 years [26]. Histological findings were noted from biopsy reports. Allografts were biopsied as per protocol or as indicated by a decline in renal function or an increase in proteinuria. ESRD was defined as initiation of dialysis or renal transplantation. Recurrence of amyloidosis in the graft was diagnosed by a kidney biopsy or determined by clinical features of new proteinuria with or without increase in creatinine in the setting of hematologic relapse. Forty-nine patients (20%) had amyloid recurrence in the graft diagnosed.

Statistics
Values are presented as median with range unless specified. We described study sample characteristics via counts and percentages for categorical variables. Differences between groups were evaluated using Cox regression analysis to determine the variables affecting overall and graft survival. Survival and recurrence rates were calculated using Kaplan–Meier method. The graft survival endpoint was defined by the need for permanent dialysis, second renal transplantation, or death. Sensitivity analyses were performed for the time to recurrence analysis using all-cause death as a competing risk [27]. Gray’s test was used to assess hypotheses of equality of cause-specific cumulative incidence functions between two groups. In addition, for the amyloid recurrence endpoint the estimates for the cumulative incidence functions (CIP) were also performed. Analysis was performed using SAS 9.3 software (SAS Institute INC., Cary, NC, USA) and p value < 0.05 was defined as statistically significant.

RESULTS
Clinical features
Baseline patient characteristics are summarized in Table 1. The median age at diagnosis was 55 years (range 26–74). Sixty percent of the patients were male and 96% of them were white. Sixty-six percent of the patients had lambda light chain amyloidosis. Only 3.8% had diabetes and 32% had high blood pressure. The majority of the patients (69%) had multiorgan involvement with 41% having cardiac, 23% liver, 16% GI, 15% peripheral nervous system, and 11% autonomic nervous system involvement. Only one patient had advanced cardiac involvement (Mayo stage 3) at diagnosis, and most had Mayo stage 1. Five patients also underwent heart transplantation, and 2 patients had combined liver-kidney transplantation.

The median serum creatinine of the patients who were not on dialysis at diagnosis was 2 mg/dL (range: 0.4–20); 176 µmol/L (range: 35–1414)), eGFR was 35.5 mL/min/1.73 m² (range 4–139), and proteinuria was 7 g per 24 h (range 0–41). The median time from diagnosis to end-stage renal disease was 1.6 years (range 0–11.5). Median overall survival from diagnosis was 14.3 years (range 1–32).

Treatment outcomes at the time of kidney transplantation
The number of patients undergoing renal transplantation has increased over the last 30 years (Fig. 1). There were 20 (8%) patients transplanted before 2000, 91 (38%) between 2000 and 2010 and 128 (53%) between 2011 and 2020. In addition, there have been an increasing number of patients who achieved CR or VGPR as a result of successful treatment (Fig. 1). Hematologic response status at the time of kidney transplantation was as follows: 145 patients with CR, 40 with VGPR, 24 with PR, 11 with NR and 19 were treatment naïve (Table 1). The majority of the patients (62%) underwent HDM/SCT. Baseline patient characteristics were not different between the patients treated with HDM/SCT or chemotherapy alone except eGFR at diagnosis which was better in the SCT group (46 vs. 34 mL/min/1.73 m², p = 0.01). The percentage of patients who underwent HDM/SCT at the different centers varied between 40% and 100%. HDM/SCT was the first line therapy in 75 patients (31%). All five patients with combined heart and kidney transplantation were treated with HDM/SCT. From the 148 patients who underwent HDM/SCT at any time point, 31 were treated after renal transplantation either as first-line treatment (treatment-naïve patients; N = 14) or for relapsed disease. Seventy percent of the patients required more than one line of therapy administered before or after kidney transplantation. About 20% of the patients received 3, 14% received 4 or more courses of treatment.

Renal transplant outcomes
Preoperative transplant assessments and postoperative immunosuppression regimens were according to local protocol. In addition to the standard selection criteria for renal transplantation [28], most of the patients who were transplanted after 1999 required sufficient suppression of the underlying plasma cell dyscrasia to prevent the progression of amyloid organ involvement.
The median age at renal transplantation was 60.8 years (range 30.6–79).

Slightly more patients had living renal transplantation than cadaveric donation (54% vs. 46%). In the United States, living donation was more common than in the European countries (% living donation: 73% vs 28%; USA vs Europe). There were 33 patients (13.8%) with preemptive renal transplants. Delayed graft function was observed in 26 patients (11%). One patient had primary graft failure due to surgical complications. The vast majority of the patients were on standard maintenance immunosuppressive regimens including prednisone, tacrolimus or cyclosporine and mycophenolate mofetil. Only six patients were on a steroid-free protocol. Azathioprine including prednisone, tacrolimus or cyclosporine and mycophenolate mofetil. Only six patients were on a steroid-free protocol. Azathioprine was part of the regimen in six patients and sirolimus was included in three patients. Induction therapy included thymoglobulin or basiliximab most of the patients.

Table 1. Baseline patient characteristics according to hematologic response status at the time of kidney transplantation.

| Characteristic                  | Overall (N = 237) | TN (N = 17) | CR (N = 145) | VGPR (N = 40) | PR (N = 24) | NR (N = 11) |
|--------------------------------|------------------|------------|-------------|--------------|------------|------------|
| Age at diagnosis (years; median) | 55 (26–74)       | 60 (34–74) | 54 (27–70)  | 54 (30–74)  | 53 (37–70) | 55 (41–64) |
| Male                           | 156 (65.8%)      | 12 (70.6%) | 91 (62.8%)  | 27 (67.5%)  | 19 (79.2%) | 7 (63.6%)  |
| Race: white                    | 228 (96%)        | 17 (100%)  | 140 (96%)   | 38 (95%)    | 23 (95%)   | 10 (100%)  |
| FLC type                       |                  |            |             |              |            |            |
| Kappa                          | 80 (34%)         | 6 (35%)    | 50 (35%)    | 10 (25%)    | 10 (42%)   | 4 (36%)    |
| Lambda                         | 157 (66%)        | 11 (65%)   | 95 (65%)    | 30 (75%)    | 14 (59%)   | 7 (64%)    |
| Creatinine at diagnosis (µmol/L)| 176 (35–1414)    | 190 (62–539)| 197 (35–1414)| 108 (35–1061)| 135 (62–875)| 163 (53–371)|
| eGFR MDRD at diagnosis         | 35.5 (2–139)     | 27 (9–97)  | 30 (2–139)  | 59 (4–135)  | 61.5 (6–127) | 42 (16–124) |
| Proteinuria (grams/24 hr)      | 7 (0–41.8)       | 3.7 (0.2–26)| 7.235 (0–41.8)| 5.6 (0–17.6)| 7.99 (0–23.2)| 7.4 (0–15.3)|
| Co-morbidities                 |                  |            |             |              |            |            |
| DM                             | 9 (3.8%)         | 0 (0%)     | 7 (4.9%)    | 1 (2.6%)    | 1 (4.2%)   | 0 (0%)     |
| Hypertension                   | 76 (32.3%)       | 8 (47.1%)  | 41 (28.5%)  | 16 (41%)    | 10 (41.7%) | 1 (9.1%)   |
| Vascular disease (CAD, MI, PAD)| 21 (8.9%)        | 2 (11.8%)  | 14 (9.7%)   | 4 (10.3%)   | 0 (0%)     | 1 (9.1%)   |
| Organ involvement              |                  |            |             |              |            |            |
| Cardiac                        | 96 (40.5%)       | 5 (29.4%)  | 57 (39.3%)  | 21 (52.5%)  | 8 (33.3%)  | 5 (45.5%)  |
| Renal                          | 226 (95.4%)      | 17 (100%)  | 136 (93.8%) | 38 (95%)    | 24 (100%)  | 11 (100%)  |
| Hepatic                        | 55 (23.2%)       | 4 (23.5%)  | 34 (23.4%)  | 8 (20%)     | 9 (37.5%)  | 0 (0%)     |
| GI                             | 38 (16%)         | 3 (17.6%)  | 20 (13.8%)  | 8 (20%)     | 5 (20.8%)  | 2 (18.2%)  |
| AN                             | 27 (11.4%)       | 3 (17.6%)  | 11 (7.6%)   | 6 (15%)     | 5 (20.8%)  | 2 (18.2%)  |
| PN                             | 36 (15.2%)       | 4 (23.5%)  | 17 (11.7%)  | 7 (17.5%)   | 6 (25%)    | 2 (18.2%)  |
| Pulmonary                      | 2 (0.8%)         | 0 (0%)     | 1 (0.7%)    | 1 (2.5%)    | 0 (0%)     | 0 (0%)     |
| Multigen involvement           | 162 (68.4%)      | 9 (52.9%)  | 95 (65.5%)  | 31 (77.5%)  | 18 (75%)   | 9 (81.8%)  |
| Type of renal transplantation   |                  |            |             |              |            |            |
| Living                         | 131 (54%)        | 14 (87.5%) | 82 (57.7%)  | 23 (60.5%)  | 8 (36.4%)  | 4 (36.4%)  |
| Cadaveric                      | 106 (46%)        | 3 (18%)    | 63 (43%)    | 17 (42%)    | 16 (66%)   | 7 (63.6%)  |

CR complete response, VGPR very good partial response, PR partial response, NR no response, TN treatment naive.

The outcomes from the second and third renal transplants are not included in the analysis.

The median time from diagnosis to renal transplantation was 3.8 years (range: −5.7–12.8), from ESRD to renal transplantation was 2 years (range 0–11.7) and from hematomatologic response to kidney transplantation was 2.2 years (range 0.4–10.4).

During the median follow-up of 11.7 years from diagnosis (range: 0.8–32) and 8.5 years from renal transplantation (range: 0–29), 90 patients (38%) died at the median age of 64.6 years (range: 36–81). The cause of death was reported to be directly related to amyloidosis in 31 patients. Overall survival from diagnosis was 14.4 years (95% CI: 12.8–16.3) and from renal transplantation 8.6 years (95% CI: 6.9–9.7). One-, three- and five-year OS from renal transplantation was 95%, 83% and 74%, respectively (Table 2).

Survival outcomes were analyzed based on the patients’ degree of hematologic response to therapy at the time of renal transplantation. OS from renal transplantation was 9 years in patients with CR + VGPR and 6.8 years in patients with PR + NR + TN (HR: 1.5, P = 0.04 [95% CI: 1.2–1.1]) (Fig. 2A). When comparing CR vs. VGPR there was no difference in OS from renal transplantation (Fig. 2D; OS from renal transplantation CR vs. VGPR: 9 vs. 6.7 years, P = 0.3).

The median time of graft survival was 7.8 years (95% CI: 6.5–9). One-, three- and five-year graft survival rates were 92%, 79% and 69%, respectively (Table 2). Death censored graft survival was better in the CR + VGPR group vs the PR + NR + TN group (8.3 vs 5.7 years, HR: 1.4, P = 0.05 [95% CI: 1.2–1.1]) (Fig. 2B) and there was no difference between the CR and VGPR groups (Fig. 2E). There was no difference in renal transplant outcomes between patients who underwent HDM/SCT versus patients who were treated only with chemotherapy. Undergoing HDM/SCT before or after renal transplantation did not change OS or transplant outcomes. Similarly, there was no statistically significant difference between living versus cadaveric renal transplantation or between lambda and kappa clonality. Cardiac involvement at baseline, the number of organs involved, acute rejection and preemptive renal transplant did not significantly affect patient or graft survival.

Amyloid recurrence after renal transplantation
Sixty-nine patients (29%) experienced hematologic relapse requiring treatment post renal transplantation. Their graft survival
was not statistically different from that of patients without relapse (7.8 vs. 11.7 years, \( p = 0.6 \)). Median time to recurrence in the graft was 6.6 years. Graft loss was reported to be amyloid related only in six patients and successful hematologic treatment prevented graft loss in 87% of patients who had amyloid recurrence in the graft.

There was a lower rate of amyloid recurrence in the graft in the CR + VGPR group compared to the PR + NR + TN group (HR: 1.6, \( p = 0.01 \) [95% CI: 1.1–2.5]) (Fig. 3). Using all-cause death as competing risk, the estimates for CIP for amyloid recurrence in the graft is shown in Supplemental Table). In addition, the time to recurrence in the graft was longer in the CR + VGPR vs the PR + NR + TN group and was similar between CR and VGPR patients (Fig. 2F).

Non-amyloid related post-transplant complications
Thirty-one patients were treated for cellular rejection and seven patients had documented antibody-mediated rejection. With the exception of six patients, the majority of these rejection episodes were treated successfully without graft loss. Post-transplant lymphoproliferative disorder was documented in five patients. The incidence and types of infectious complications post renal transplantation were not available in the majority of patients.

DISCUSSION

New, effective systemic therapies that successfully target pathologic plasma cells and suppress toxic light chain production have led to an increase in the number of patients who survive longer albeit with ESRD. There is a lingering reluctance to offer renal transplantation to these patients due to the fear of recurrent disease and poor outcomes. Therefore, there is an urgent need to identify patients who may benefit. To address this need, we combined data from five countries under the umbrella of The International Kidney and Monoclonal Gammapathy Research Group which resulted in the largest series of patients with AL amyloidosis who underwent renal transplantation.

These data show excellent outcomes: OS from diagnosis was 14.4 years and from renal transplantation 8.6 years. The long post-diagnosis OS (compared to all AL amyloid patients) shows that these are highly selected patients with excellent response to therapeutic interventions. The median time of graft survival was also very good, 7.8 years and compared favorably to outcomes reported for patients who were transplanted for non-amyloidosis indications. This was despite the age of our patients at renal transplantation being a decade older than the average renal transplant recipient (60.8 vs. 50 years). There was no statistically significant difference between living versus cadaveric renal transplantation but this question should be revisited in a larger cohort less dependent on selection bias.

Transplant outcomes were analyzed based on the degree of hematologic response to therapy at the time of renal transplantation. Our results confirmed previous observations showing better outcomes with deeper hematologic response. Overall survival was better and amyloid recurrence rate was lower in the CR + VGPR group. Most of the patients in our cohort had achieved CR or VGPR (77%) at the time of renal transplantation suggesting a potential selection bias. Patients in the PR, NR, and TN groups were mainly from the era when therapeutic options were limited and therefore, not surprisingly, their outcomes are worse. Importantly, these cases provide insight into the natural history of AL amyloidosis after renal transplantation in untreated or undertreated patients. Regardless, our results support the preferential selection of patients for renal transplantation who achieved CR and VGPR.

However, median renal graft survival was still over 5 years in patients with less favorable hematologic responses at the time of transplantation. Identifying patients in this group who are most likely to benefit from renal allograft and understanding the quality of life implications of undergoing renal transplantation compared to remaining on renal replacement therapy should be the subject of future studies. Importantly, we could not find statistically significant difference in outcomes between CR and VGPR based on our cohort. Future studies should re-address this question after inclusion of more patients specially in the VGPR group.

Although patients received various treatment modalities, the majority of them (62%) underwent HDM/SCT at some point during the study period. Outcomes were superior in patients with hematologic response regardless of the treatment regimen they received. Plasma cell-directed therapy should be administered prior to renal transplantation, although a small number of patients who were treatment naive had good outcomes after undergoing HDM/SCT following renal transplantation. This group consisted of only six patients precluding any definitive conclusions from the experience of these patients.
Notably, only six allografts failed due to recurrent amyloid although one third (n = 69) of the patient experienced hematologic relapse after renal transplantation and required additional hematologic treatment. This proves that newer, more effective therapies can treat AL amyloidosis successfully and prevent graft loss.

The median time from ESRD to renal transplantation was 2 years and from hematologic response was 2.2 years. This time delay resulted from the combination of the wait time on the deceased donor list, the time that required to complete the transplant evaluation (both the donor and recipient in the case of living donation), observation period after completing treatment to document the durability of response and patients’ and physicians’ preferences regarding timing of the surgery. In our cohort we had no patients who were being actively treated for amyloidosis in peri-transplant period.

Cardiac and multi-organ involvement did not influence outcomes in our patient population, likely because patients with advanced extra-renal organ involvement were generally not considered for renal transplantation. In fact, only one patient who had advanced cardiac involvement (Mayo stage 3) was included in our dataset. All the patients received standard immunosuppressive regimens according to local protocols and they didn’t seem to have more frequent rejection episodes than is commonly seen in other renal transplant populations.

Previous studies have described smaller numbers patients with AL amyloidosis who underwent kidney transplantation [17–21, 29]. The Mayo Clinic reported a median OS from kidney transplantation of 10.3 years among 60 patients transplanted between 1997 and 2018 [19]. Death-censored graft survival at one- and five-years was 98.3% and 95.8%, respectively. When divided according to hematologic response, median OS was not reached for the combined CR + VGPR group and was 3.9 years for the PR + NR group. Of their 60 patients, three had allograft failure, 19 died with a functioning graft, and 13 had amyloid recurrence in the graft.

The Amyloidosis Center at Boston University also reported similar median OS of 49 patients: 15.3 years from diagnosis and 10.5 years from renal transplantation [17]. One- and five-year graft survival were 94% and 81%, respectively. Patients with CR + VGPR at renal transplantation had a better OS than patients with PR + NR (17.9 versus 9.7 years; HR 2.5, P = 0.03). Median time to graft loss in patients with CR + VGPR was 10.4 years and with PR + NR was 5.5 years (HR 1.8, P = 0.15). Both patient and graft survival were comparable to outcomes achieved in non-AL amyloidosis patients. The UK National Amyloidosis Center reported 50 AL amyloidosis patients that underwent renal transplantation in the past 15 years. Sixty percent of patients had CR at the time of renal transplantation and 15% had VGPR. Overall survival from renal transplantation was 9 years [18]. In their cohort patients who achieve CR had better survival than patients with VGPR which led to their conclusion that patients should achieve CR before consideration for renal transplantation. In a smaller cohort from Memorial Sloan Kettering Cancer Center, all treated with HDM/SCT, at the time of renal transplantation 14/16 patients had achieved a hematologic VGPR or better while the other two had hematologic progression. During a median follow-up time of 10 years, four patients experienced hematological progression and all four successfully received salvage therapy [21].

While single-center studies offer important insight about certain populations, one of the major strengths of our study is the inclusion of patients from five different countries who were not necessarily treated uniformly. The extended follow-up, 11.7 years from diagnosis and 8.5 years from renal transplantation and the number of patients included, resulting in the largest published series, are other notable strengths.

While this study represents the largest published cohort to date, we acknowledge several limitations that decrease the generalizability of our findings. The vast majority of patients included

| Table 2. Comparison of major renal transplant outcomes among various patient groups. |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| US [31, 32] | Europe [31, 32] | USRDS 2017 [33] | Our cohort (AL amyloidosis) | USRDS 2017 [33] | (All types of amyloidosis) | USRDS 2017 [33] | (All etiologies) |
| Number of patients | N/A | N/A | 237 | 576 | 5.8 | 15.2 | N/A |
| Overall survival (years from renal Tx) | N/A | N/A | 1 yr | 8.6 | 5.8 | 8.6 | N/A |
| Graft survival (years) | N/A | N/A | 1 yr | 9.7% | 9.7% | 9.7% | 9.7% |
| Overall survival (years) | N/A | N/A | 3 yrs | 96% | 96% | 96% | 96% |
| Graft survival (years) | N/A | N/A | 5 yrs | 6% | 6% | 6% | 6% |
| Graft survival (years) | N/A | N/A | 1 yr | 100% | 100% | 100% | 100% |
| Graft survival (years) | N/A | N/A | 3 yrs | 70% | 70% | 70% | 70% |
| Graft survival (years) | N/A | N/A | 5 yrs | 69% | 69% | 69% | 69% |

USRDS The United States Renal Data System, DM diabetes mellitus, N/A not applicable.
were Caucasian. This bias is mainly due to the demographics of the countries participating in the study but, under-diagnosis of AL amyloidosis in other ethnicities and the racial and ethnic disparities in access to renal transplant likely also contributed [30]. Another factor that led to heterogeneity in identifying amyloid recurrence in the graft includes protocol versus clinically indicated biopsies. Protocol biopsies might have led to earlier detection and treatment of amyloid recurrence in the graft when
compared to patients whose grafts were biopsied only when it was clinically indicated. Treatment decisions regarding modalities and timing were physician dependent and might have led to bias. Eligibility for kidney transplantation was also determined locally potentially leading to variability in patient selection. Lastly, a large majority of the data was collected retrospectively.

Despite these limitations, our results clearly show that selected patients with AL amyloidosis undergoing kidney transplantation have excellent outcomes. Our consensus is that patients who achieve CR or VGPR using the current International Society of Amyloidosis criteria [25] should be considered for renal transplantation if other standard renal transplant criteria are also met. Renal transplantation prolongs survival and offers a much-needed improvement in the quality of life for these patients. However, close monitoring and carefully selected therapeutic strategies should be administered by a multidisciplinary team involving hematologists, nephrologists, and transplant surgeons with experience in the treatment of this rare disease.

**DATA AVAILABILITY**

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

**REFERENCES**

1. Merlino G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349:583–96.
2. Merlino G, Dispensiari A, Sanchorawala V, Schönland SO, Palladini G, Hawkins PN, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Prim. 2018;4:38.
3. Impellini E, Gnecci M, Rognoni P, Sabido E, Ciuffreda MC, Palladini G, et al. Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells. Sci Rep. 2017;7:15661.
4. Merlino G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011;29:1924–33.
5. Gertz MA, Leung N, Lacy MQ, Dispensiari A, Zeldennsrt SR, Hayman SR, et al. Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrol Dial Transpl. 2009;24:3132–7.
6. Havaszi A, Stern L, Lo S, Sun F, Sanchorawala V. Validation of new renal staging system in AL amyloidosis treated with high dose melphalan and stem cell transplantation. Am J Hematol. 2016;91:458–60.
7. Palladini G, Hegenhart U, Milani P, Kimmich C, Foli A, Ho AD, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014;124:2325–32.
8. Pinney JH, Lachmann HJ, Bansi I, Wechalekar AD, Gilbertson JA, Rowczzenio D, et al. Outcome in renal AI amyloidosis after chemotherapy. J Clin Oncol. 2011;29:674–81.
9. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997;336:1202–7.
10. Skinner M, Anderson J, Simms R, Fulk R, Wang M, Libby C, et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med. 1996;100:290–8.
11. Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk J, Dember LM, et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood. 2011;118:4346–52.
12. Kaufman GP, Schrier SL, Lafayette RA, Arai S, Wittes RM, Liedtke M, Dar- atumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood. 2017;130:900–2.
13. Szalat R, Sarosiek S, Havaszi A, Brauneis D, Sloan JM, Sanchorawala V. Organ response after highdose melphalan and stemcell transplantation in AL amyloidosis. Leukemia. 2021;35:916–9.
14. Kaufman GP, Dispensiari A, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, et al. Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. Am J Hematol. 2015;90:181–6.
15. Pasternack A, Ahonen J, Kuhlback B. Renal transplantation in 45 patients with amyloidosis. Transplantation. 1986;42:598–601.
16. Dorman SA, Gamelli RL, Benziger JR, Trainer TD, Foster RS. Systemic amyloidosis involving two renal transplants. Hum Pathol. 1981;12:735–8.
17. Angel-Korman A, Stern L, Sarosiek S, Sloan JM, Doros G, Sanchorawala V, et al. Long-term outcome of kidney transplantation in AL amyloidosis. Kidney Int. 2019;95:405–11.
18. Cohen OC, Law S, Lachmann HJ, Sharphey F, Ravichandran S, Mahmod S, et al. The impact and importance of achieving a complete haematological response prior to renal transplantation in AL amyloidosis. Blood Cancer J. 2020;10:60.
19. Heybeli C, Bentall A, Wen J, Alexander MP, Buadi FK, Cosio FG, et al. A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis. Kidney Int. 2021;99:707–15.
20. Law S, Cohen O, Lachmann HJ, Rezk T, Gilbertson JA, Rowczzenio D, et al. Renal transplant outcomes in amyloidosis. Nephrol Dial Transpl. 2021;36:355–65.
21. Sathick U, Rosenbaum CA, Gutgarts V, Landau H. Kidney transplantation in AL Amyloidosis: is it time to maximize access? Br J Haematol. 2020;188:e1–4.
22. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005;79:319–28.
23. Palladini G, Russo P, Bosoni T, Verga L, Sarais G, Lavatelli F, et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem. 2009;55:499–504.
24. Palladini G, Dispensiari A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in immunoglobulin light chain amyloi- dosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30:4511–9.
25. Palladini G, Schönland SO, Sanchorawala V, Kumar S, Wechalekar A, Hegenhart U, et al. Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis. Amyloid. 2021;28:1–2.
26. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–70.
27. Dignam JJ, Kocherginsky MN. Choice and interpretation of statistical tests used when competing risks are present. J Clin Oncol. 2008;26:4027–34.
28. Kidney Disease: Improving Global Outcomes Transplant Work G. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transpl. 2009;9:s1–155.
29. Hermann SM, Gertz MA, Stiggall MD, Dispensiari A, Cosio FC, Kumar S, et al. Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrol Dial Transpl. 2011;26:2032–6.
30. Staron A, Connors LH, Zheng L, Doros G, Sanchorawala V. Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities. Blood Cancer J. 2020;10:118.
31. Wang X, Skeans MA, Israni AK. Current status of kidney transplant outcomes: dying to survive. Adv Chronic Kidney Dis. 2016;23:281–6.
32. Hart A, Smith JM, Skeans MA, Gustafson SK, Wilk AR, Robinson A, et al. OPTN/SRTR 2016 Annual Data Report: Kidney. Am J Transpl. 2018;18:113–113.
33. Sawinski D, Lim MA, Cohen JC, Locke JE, Weiss B, Hogan JJ, et al. Patient and kidney allograft survival in recipients with end stage renal disease from Amyloidosis. Transplantation. 2018;102:300–9.
AUTHOR CONTRIBUTIONS
AH, HL: conceptualization, data curation, review and editing, writing original draft, review and editing. CH, NL, AAK, VS, OC, AW, FB, JJ, VG, HH, ML, CR, PM, GP, GM, UH, SS, and KV: conceptualization, data curation, review and editing. AP, GD: formal analysis, methodology.

FUNDING
This research was funded in part through NIH/NCI Cancer Center Support Grant P30 CA008748 (HL); McCaleb Award from the Amyloidosis Center, Boston University School of Medicine, Alan and Sandra Gerry Amyloid Research Laboratory (AH).

COMPETING INTERESTS
VS: Research support from Celgene, Takeda, Caelum, Prothena, Janssen. Advisory boards of Regeneron, Abbvie, Janssen, Caelum; Consultancy for Pfizer. UH: Grants from Janssen, Prothena, and Pfizer. Advisory boards for Pfizer, Janssen, and Prothena. Honoraria from Janssen, Pfizer, Alnylam, and Akcea. Research funding from Janssen. SOS: Travel grants from Janssen, MSD, Prothena and Takeda, Advisory boards for Janssen and Prothena. Honoraria from Janssen, Prothena, Pfizer, and Takeda. Research funding from Sanofi and Janssen. HL: Advisory board for Janssen, Celgene, Sanofi, Takeda, Caelum, Pfizer. Honoraria from Pfizer and Sanofi. Research funding from Takeda. GP: Honoraria and advisory board of Janssen-Cilag, Honoraria Pfizer and Siemens. PM: Speaker honoraria Janssen-Cilag, Honoraria Pfizer and Siemens. FB: Honoraria from Astra-Zeneca and Janssen. AH: At the time of publication employed by Alnylam Pharmaceuticals. At the time of data collection, analysis and writing of the paper no disclosure.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41408-022-00714-5.

Correspondence and requests for materials should be addressed to Andrea Havasi.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022